Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk and Merrion expand deal

This article was originally published in Scrip

Executive Summary

Novo Nordiskand Merrion Pharmaceuticalshave signed another development and licence agreement for the production of oral insulin formulations of a GLP-1 receptor agonist using the Irish company's GIPET technology. Novo Nordisk will pay Merrion $58 million for the first marketed product developed under the agreement and will be responsible for the development and commercialisation of all product candidates. Merrion will develop and manufacture initial clinical batches of the product, which will be overseen by a joint development committee. Novo Nordisk may also develop additional oral formulations of its GLP-1 receptor agonist compounds using the GIPET technology, in which case Merrion would receive additional milestone payments for any products developed. Novo Nordisk will buy 300,000 of Merrion's new ordinary shares for €3 per share. The two companies signed a development agreement for oral insulin analogues in November (ScripOnline, December 2nd, 2008).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007701

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel